Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma

Shinichi Toyooka, Toshimi Takano, Takayuki Kosaka, Katsuyuki Hotta, Keitaro Matsuo, Shuji Ichihara, Yoshiro Fujiwara, Junichi Sou, Hiroki Otani, Katsuyuki Kiura, Keisuke Aoe, Yasushi Yatabe, Yuichiro Ohe, Tetsuya Mitsudomi, Hiroshi Date

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Epidermal growth factor receptor (EGFR) mutations have been reported as a predictive factor for favorable prognosis of gefitinib-treated patients with lung adenocarcinoma. However, its confounding with sex and smoking makes it unclear whether the EGFR mutation is independently associated with prolonged patient survival. In this study, we analyzed a large-scale database to discriminate the survival impact of EGFR mutations against those of sex and smoking after gefitinib therapy. EGFR mutations in exon19 and exon21 named drug-sensitive EGFR mutations were examined to investigate the impact of EGFR mutation, sex, and smoking status on survival of 362 gefitinib-treated patients with lung adenocarcinoma. Drug-sensitive EGFR mutations were detected in 169 patients (46.7%). The multivariate analysis including EGFR, sex, and smoking status showed that drug-sensitive EGFR mutations were significantly related to longer overall survival (OS) (P <0.001) and progression-free survival (PFS) (P <0.001). In addition, we investigated the impact of sex and smoking status according to EGFR mutation status, and the impact of EGFR mutation status according to sex and smoking status on survival. Sex and smoking status were not significantly associated with longer OS and PFS according to EGFR mutation status. Drug-sensitive EGFR mutations were significantly associated with longer OS and PFS according to sex or smoking status. Our results indicated that drug-sensitive EGFR mutations were the only independent factor for longer survival of patients treated with gefitinib, suggesting that patient selection based on EGFR mutation status for gefitinib therapy will lead to a better outcome for patients with lung adenocarcinoma.

Original languageEnglish
Pages (from-to)303-308
Number of pages6
JournalCancer Science
Volume99
Issue number2
DOIs
Publication statusPublished - Feb 2008

Fingerprint

Epidermal Growth Factor Receptor
Smoking
Mutation
Survival
Disease-Free Survival
Pharmaceutical Preparations
gefitinib
Adenocarcinoma of lung
Patient Selection
Multivariate Analysis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma. / Toyooka, Shinichi; Takano, Toshimi; Kosaka, Takayuki; Hotta, Katsuyuki; Matsuo, Keitaro; Ichihara, Shuji; Fujiwara, Yoshiro; Sou, Junichi; Otani, Hiroki; Kiura, Katsuyuki; Aoe, Keisuke; Yatabe, Yasushi; Ohe, Yuichiro; Mitsudomi, Tetsuya; Date, Hiroshi.

In: Cancer Science, Vol. 99, No. 2, 02.2008, p. 303-308.

Research output: Contribution to journalArticle

Toyooka, Shinichi ; Takano, Toshimi ; Kosaka, Takayuki ; Hotta, Katsuyuki ; Matsuo, Keitaro ; Ichihara, Shuji ; Fujiwara, Yoshiro ; Sou, Junichi ; Otani, Hiroki ; Kiura, Katsuyuki ; Aoe, Keisuke ; Yatabe, Yasushi ; Ohe, Yuichiro ; Mitsudomi, Tetsuya ; Date, Hiroshi. / Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma. In: Cancer Science. 2008 ; Vol. 99, No. 2. pp. 303-308.
@article{3c209dbf06234fef979592a1719ded1a,
title = "Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma",
abstract = "Epidermal growth factor receptor (EGFR) mutations have been reported as a predictive factor for favorable prognosis of gefitinib-treated patients with lung adenocarcinoma. However, its confounding with sex and smoking makes it unclear whether the EGFR mutation is independently associated with prolonged patient survival. In this study, we analyzed a large-scale database to discriminate the survival impact of EGFR mutations against those of sex and smoking after gefitinib therapy. EGFR mutations in exon19 and exon21 named drug-sensitive EGFR mutations were examined to investigate the impact of EGFR mutation, sex, and smoking status on survival of 362 gefitinib-treated patients with lung adenocarcinoma. Drug-sensitive EGFR mutations were detected in 169 patients (46.7{\%}). The multivariate analysis including EGFR, sex, and smoking status showed that drug-sensitive EGFR mutations were significantly related to longer overall survival (OS) (P <0.001) and progression-free survival (PFS) (P <0.001). In addition, we investigated the impact of sex and smoking status according to EGFR mutation status, and the impact of EGFR mutation status according to sex and smoking status on survival. Sex and smoking status were not significantly associated with longer OS and PFS according to EGFR mutation status. Drug-sensitive EGFR mutations were significantly associated with longer OS and PFS according to sex or smoking status. Our results indicated that drug-sensitive EGFR mutations were the only independent factor for longer survival of patients treated with gefitinib, suggesting that patient selection based on EGFR mutation status for gefitinib therapy will lead to a better outcome for patients with lung adenocarcinoma.",
author = "Shinichi Toyooka and Toshimi Takano and Takayuki Kosaka and Katsuyuki Hotta and Keitaro Matsuo and Shuji Ichihara and Yoshiro Fujiwara and Junichi Sou and Hiroki Otani and Katsuyuki Kiura and Keisuke Aoe and Yasushi Yatabe and Yuichiro Ohe and Tetsuya Mitsudomi and Hiroshi Date",
year = "2008",
month = "2",
doi = "10.1111/j.1349-7006.2007.00688.x",
language = "English",
volume = "99",
pages = "303--308",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma

AU - Toyooka, Shinichi

AU - Takano, Toshimi

AU - Kosaka, Takayuki

AU - Hotta, Katsuyuki

AU - Matsuo, Keitaro

AU - Ichihara, Shuji

AU - Fujiwara, Yoshiro

AU - Sou, Junichi

AU - Otani, Hiroki

AU - Kiura, Katsuyuki

AU - Aoe, Keisuke

AU - Yatabe, Yasushi

AU - Ohe, Yuichiro

AU - Mitsudomi, Tetsuya

AU - Date, Hiroshi

PY - 2008/2

Y1 - 2008/2

N2 - Epidermal growth factor receptor (EGFR) mutations have been reported as a predictive factor for favorable prognosis of gefitinib-treated patients with lung adenocarcinoma. However, its confounding with sex and smoking makes it unclear whether the EGFR mutation is independently associated with prolonged patient survival. In this study, we analyzed a large-scale database to discriminate the survival impact of EGFR mutations against those of sex and smoking after gefitinib therapy. EGFR mutations in exon19 and exon21 named drug-sensitive EGFR mutations were examined to investigate the impact of EGFR mutation, sex, and smoking status on survival of 362 gefitinib-treated patients with lung adenocarcinoma. Drug-sensitive EGFR mutations were detected in 169 patients (46.7%). The multivariate analysis including EGFR, sex, and smoking status showed that drug-sensitive EGFR mutations were significantly related to longer overall survival (OS) (P <0.001) and progression-free survival (PFS) (P <0.001). In addition, we investigated the impact of sex and smoking status according to EGFR mutation status, and the impact of EGFR mutation status according to sex and smoking status on survival. Sex and smoking status were not significantly associated with longer OS and PFS according to EGFR mutation status. Drug-sensitive EGFR mutations were significantly associated with longer OS and PFS according to sex or smoking status. Our results indicated that drug-sensitive EGFR mutations were the only independent factor for longer survival of patients treated with gefitinib, suggesting that patient selection based on EGFR mutation status for gefitinib therapy will lead to a better outcome for patients with lung adenocarcinoma.

AB - Epidermal growth factor receptor (EGFR) mutations have been reported as a predictive factor for favorable prognosis of gefitinib-treated patients with lung adenocarcinoma. However, its confounding with sex and smoking makes it unclear whether the EGFR mutation is independently associated with prolonged patient survival. In this study, we analyzed a large-scale database to discriminate the survival impact of EGFR mutations against those of sex and smoking after gefitinib therapy. EGFR mutations in exon19 and exon21 named drug-sensitive EGFR mutations were examined to investigate the impact of EGFR mutation, sex, and smoking status on survival of 362 gefitinib-treated patients with lung adenocarcinoma. Drug-sensitive EGFR mutations were detected in 169 patients (46.7%). The multivariate analysis including EGFR, sex, and smoking status showed that drug-sensitive EGFR mutations were significantly related to longer overall survival (OS) (P <0.001) and progression-free survival (PFS) (P <0.001). In addition, we investigated the impact of sex and smoking status according to EGFR mutation status, and the impact of EGFR mutation status according to sex and smoking status on survival. Sex and smoking status were not significantly associated with longer OS and PFS according to EGFR mutation status. Drug-sensitive EGFR mutations were significantly associated with longer OS and PFS according to sex or smoking status. Our results indicated that drug-sensitive EGFR mutations were the only independent factor for longer survival of patients treated with gefitinib, suggesting that patient selection based on EGFR mutation status for gefitinib therapy will lead to a better outcome for patients with lung adenocarcinoma.

UR - http://www.scopus.com/inward/record.url?scp=38949169542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38949169542&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2007.00688.x

DO - 10.1111/j.1349-7006.2007.00688.x

M3 - Article

C2 - 18271929

AN - SCOPUS:38949169542

VL - 99

SP - 303

EP - 308

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 2

ER -